Where Gross-to-net Pressure Actually Lives After Launch

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Cindy explains that many gross-to-net (GTN) exposures now occur at the claim level, where evolving payer tactics, pharmacy economics, and copay complexity create unpredictable leakage. She argues that manufacturers must augment downstream review with real-time visibility and intervention to protect both revenue and patient access.

To learn more, register for ConnectiveRx’s free webinar on June 17: Gross-To-Net FOMO: What GTN Dangers Are You Missing Post-Launch?

Read on for Cindy’s insights.

Where Gross-to-net Pressure Actually Lives After Launch
By Cindy Baksh, Chief Product Officer, ConnectiveRx

If you are part of the team that has responsibility for a pharmaceutical brand’s access strategy, you already understand the effort required to build GTN assumptions ahead of launch. Rebates get modeled, distribution and channel fees get negotiated, payer contracts get set. Those numbers are baked into forecasts. That part of the job is hard, but it is somewhat predictable.

After launch, forecasts meet the market. Besides volume and trajectory realities, a variety of pharmacy and payor-based initiatives—from switches to maximizers—can start to influence GTN. A copay program business rule that looked airtight on paper turns out to have an exception that was impossible to flag. Program dollars start flowing in directions nobody designed.

This is where GTN pressure has changed shape. It now sits outside what standard planning tools were built to see: the intersection of payer mechanics, pharmacy economics, and claim behavior.

Known risk versus the kind you can't model

Planned risks are the ones manufacturers can quantify before a drug reaches a patient: rebates, distribution fees, and contracted payer dynamics. These are known.

The risks that hurt the most sit somewhere else. US manufacturers spend over $20 billion a year on copay assistance. Per our data-based estimates, billions are lost to misuse. Accumulators and maximizers shift in real time. Pharmacy economics have squeezed retail margins, turning manipulation and product switching into survival behavior. Business rules behave differently in reality than they read on paper.

These are unknown exposures that brand teams are accountable for but can’t predict—and do not become visible until the spend has left the building.

Market evolution requires innovation

The signals came early. Payer tactics were evolving faster than program design could keep up with and pharmacy behavior was creating a new category of exposure. The center of gravity for GTN pressure was shifting out of pricing and into copay execution at the claim level.

Many of those signals emerge through our broader pharmacy monitoring service, which has run at scale for years. It detects pattern shifts across the market before the individual brand sees them. 10’s of millions were saved for clients. However, investments and technology allowed ConnectiveRx to build intervention points upstream of the spend, assume payer tactics and determine pharmacy economics.

One platform, control across the Rx lifecycle

ConnectiveRx built a fully integrated GTN platform that protects revenue at every step of the patient and Rx journey. It intervenes in real time, deploying targeted tactics against each form of leakage at the point where it emerges.

Four controls work together inside the platform.

Advanced adjudication and dynamic business rules ensure the right benefit reaches the right patient, adapting as patient and payer circumstances shift.

ShieldRx is our real-time pharmacy intervention, stopping misuse at the moment of adjudication, before money goes out the door.

Pre-claim maximizer detection flags payer tactics that would siphon off copay benefit, so risk is identified and addressed before the first dollar is spent.

Gatekeeper screens for eligibility and government coverage before claims enter the program, keeping benefit dollars intact.

Each control delivers value on its own, and many brands start by addressing the area with greatest exposure. Together, they protect brand economics while keeping copay dollars with the patients who need them, turning the program into an active lever for access. Brand teams gain visibility and intervention capability at a level they have not had before.

The most uncomfortable GTN pressure comes from what you can’t confidently predict at launch—but are still accountable for.

Register for our free webinar on June 17 at 12:00 pm ET, Gross-To-Net FOMO: What GTN Dangers Are You Missing Post-Launch?, for a conversation with pharma leaders whose responsibilities span brand commercial performance and brand financial accountability.

---

Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).